Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Adult (1)
- Aged (1)
- Alopecia areata (1)
- Antineoplastic Agents (1)
- Antineoplastic agents (1)
-
- Carcinoma (1)
- Carcinoma, Squamous Cell (1)
- Cell Cycle Proteins (1)
- Cell cycle proteins (1)
- Epidermolysis Bullosa Dystrophica (1)
- Epidermolysis bullosa dystrophica (1)
- Female (1)
- Glycine (1)
- Hairy tongue (1)
- Humans (1)
- Male (1)
- Middle Aged (1)
- Middle aged (1)
- Polo-Like Kinase 1 (1)
- Polo-like kinase 1 (1)
- Protein Serine-Threonine Kinases (1)
- Protein serine-threonine kinases (1)
- Proto-Oncogene Proteins (1)
- Proto-oncogene proteins (1)
- Quality of Life (1)
- Quality of life (1)
- Skin Neoplasms (1)
- Skin neoplasms (1)
- Squamous cell (1)
- Sulfones (1)
Articles 1 - 2 of 2
Full-Text Articles in Chemical Actions and Uses
Efficacy And Safety Of Rigosertib In Patients With Recessive Dystrophic Epidermolysis Bullosa-Associated Advanced/Metastatic Cutaneous Squamous Cell Carcinoma, Martin Laimer, Andrew P. South, Elisabeth Mayr, Sophie Kitzmueller, Lauren Banner, Michael Alexander, Linda Hosler, Henry Yang, Matthew Parris, Meena Arora, Georg Zimmermann, Gregor Schweighofer-Zwink, Johann Bauer, Neda Nikbakht
Efficacy And Safety Of Rigosertib In Patients With Recessive Dystrophic Epidermolysis Bullosa-Associated Advanced/Metastatic Cutaneous Squamous Cell Carcinoma, Martin Laimer, Andrew P. South, Elisabeth Mayr, Sophie Kitzmueller, Lauren Banner, Michael Alexander, Linda Hosler, Henry Yang, Matthew Parris, Meena Arora, Georg Zimmermann, Gregor Schweighofer-Zwink, Johann Bauer, Neda Nikbakht
Department of Dermatology and Cutaneous Biology Faculty Papers
BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is an epithelial fragility disease primarily affecting the skin and is caused by variants in the COL7A1 gene. Individuals with RDEB are predisposed to develop highly aggressive cutaneous squamous cell carcinomas (SCCs) which are the most common cause of premature death. There is a lack of effective prevention or treatment options for patients with RDEB-SCC.
OBJECTIVES: To evaluate the antitumour activity and safety of the polo-like kinase-1 (PLK1) inhibitor, rigosertib, two investigator-initiated open-label, single-arm phase II studies were opened in Europe and the USA and enrolled five patients with RDEB diagnosed with locally advanced …
Hairy Tongue Associated With The Use Of Baricitinib Therapy For Ophiasis Pattern Alopecia Areata, Anthony Gaspari
Hairy Tongue Associated With The Use Of Baricitinib Therapy For Ophiasis Pattern Alopecia Areata, Anthony Gaspari
Department of Dermatology and Cutaneous Biology Faculty Papers
We report a case of hairy tongue that developed in a young Caucasian
/="/">woman during systemic baricitinib therapy for severe alopecia areata.
/="/">Because she experienced good clinical regrowth of her hair during
/="/">treatment, she did not want to interrupt therapy. We recommended she
/="/">use a toothbrush to debride her tongue on a daily basis, which was
/="/">successful. Hairy tongue most commonly occurs in elderly, debilitated
/="/">males with poor oral hygiene. It is thought to occur because of overgrowth
/="/">of chromogenic bacteria and/or yeast on the tongue. This unusual side
/="/">effect during baricitinib …